Insider · CIK 0001220049
Nicole Onetto
Files at BOLT (Bolt Biotherapeutics, Inc.). First filing -, latest -.
Nicole Onetto files SEC Form 4 as director at BOLT (Bolt Biotherapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Nicole Onetto has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jun 11, 2026 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +1,393 | - | - | 1,393 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -1,393 | - | - | 0 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +1,107 | - | - | 1,107 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -1,107 | - | - | 0 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +611 | - | - | 611 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -611 | - | - | 0 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +1,250 | - | - | 1,250 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -1,250 | - | - | 0 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +1,250 | - | - | 1,250 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -1,250 | - | - | 0 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +1,100 | - | - | 1,100 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -1,100 | - | - | 0 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +1,100 | - | - | 1,100 | Dec 16, 2025 |
| Dec 12, 2025 | BOLT Bolt Biotherapeutics, Inc. | DDisposition to issuer Director Stock Option (Right to Buy)derivative | -1,100 | - | - | 0 | Dec 16, 2025 |
| May 27, 2025 | BOLT Bolt Biotherapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,100 | $0.00 | $0 | 1,100 | Jul 2, 2025 |
Questions about Nicole Onetto
Answered from the filings on this page, as of the latest one.
Is Nicole Onetto buying or selling?
Nicole Onetto has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Nicole Onetto's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nicole Onetto has 0.
Where does Nicole Onetto file Form 4?
Nicole Onetto has filed Form 4 at BOLT (Bolt Biotherapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.